Heparin-mimetic sulfated peptides with modulated affinities for heparin-binding peptides and growth factors

[1]  E. Furst,et al.  Growth factor mediated assembly of cell receptor-responsive hydrogels. , 2007, Journal of the American Chemical Society.

[2]  Kristi L Kiick,et al.  Manipulation of hydrogel assembly and growth factor delivery via the use of peptide-polysaccharide interactions. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[3]  A. Panitch,et al.  Viscoelastic Behavior of Environmentally Sensitive Biomimetic Polymer Matrices , 2006 .

[4]  You Han Bae,et al.  Polymer Architecture and Drug Delivery , 2006, Pharmaceutical Research.

[5]  H. Gabius,et al.  Galectins bind to the multivalent glycoprotein asialofetuin with enhanced affinities and a gradient of decreasing binding constants. , 2005, Biochemistry.

[6]  J. Hubbell,et al.  Discovery of a sulfated tetrapeptide that binds to vascular endothelial growth factor. , 2005, Acta biomaterialia.

[7]  Kristi L Kiick,et al.  Rheological characterization of polysaccharide-poly(ethylene glycol) star copolymer hydrogels. , 2005, Biomacromolecules.

[8]  K. Kiick,et al.  Polysaccharide-poly(ethylene glycol) star copolymer as a scaffold for the production of bioactive hydrogels. , 2005, Biomacromolecules.

[9]  Kam W Leong,et al.  Controlled release from fibers of polyelectrolyte complexes. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[10]  K. Ishida,et al.  Novel heparan sulfate mimetic compounds as antitumor agents. , 2004, Chemistry & biology.

[11]  Martin Ehrbar,et al.  Cell‐demanded release of VEGF from synthetic, biointeractive cell‐ingrowth matrices for vascularized tissue growth , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  M. Brenner,et al.  Controlled release of nerve growth factor enhances sciatic nerve regeneration , 2003, Experimental Neurology.

[13]  A. Panitch,et al.  Physical polymer matrices based on affinity interactions between peptides and polysaccharides. , 2003, Biomacromolecules.

[14]  Vladimir P Torchilin,et al.  Peptide and protein drug delivery to and into tumors: challenges and solutions. , 2003, Drug discovery today.

[15]  V. Sasisekharan,et al.  Structural specificity of heparin binding in the fibroblast growth factor family of proteins , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Meldal,et al.  Preparation of novel O-sulfated amino acid building blocks with improved acid stability for Fmoc-based solid-phase peptide synthesis , 2002 .

[17]  R. Linhardt,et al.  Heparin-protein interactions. , 2002, Angewandte Chemie.

[18]  T. Dam,et al.  Thermodynamic studies of lectin-carbohydrate interactions by isothermal titration calorimetry. , 2002, Chemical reviews.

[19]  M. Ishihara,et al.  Heparin-carrying polystyrene (HCPS)-bound collagen substratum to immobilize heparin-binding growth factors and to enhance cellular growth. , 2001, Journal of biomedical materials research.

[20]  J. Hubbell,et al.  Covalently conjugated VEGF--fibrin matrices for endothelialization. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[21]  M. Ueki,et al.  Synthesis and anti-HIV activity of nonatyrosine N- and O1-9-decasulfate. , 2001, Bioorganic & medicinal chemistry.

[22]  N. Perrimon,et al.  Heparan sulfate proteoglycans are critical for the organization of the extracellular distribution of Wingless. , 2001, Development.

[23]  G. Stein,et al.  Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure. , 2000, Kidney international.

[24]  S. Futaki,et al.  Stabilization of a tyrosine O-sulfate residue by a cationic functional group: formation of a conjugate acid-base pair. , 2000, The journal of peptide research : official journal of the American Peptide Society.

[25]  S J Tendler,et al.  Surface plasmon resonance analysis of dynamic biological interactions with biomaterials. , 2000, Biomaterials.

[26]  N. Perrimon,et al.  Role of heparan sulfate proteoglycans in cell-cell signaling in Drosophila. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[27]  J. Hubbell,et al.  Development of fibrin derivatives for controlled release of heparin-binding growth factors. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[28]  C. Bertozzi,et al.  Tyrosine sulfation: a modulator of extracellular protein-protein interactions. , 2000, Chemistry & biology.

[29]  A A Poot,et al.  Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[30]  W. Chan,et al.  Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Practical Approach Series) , 2019 .

[31]  Joseph Sodroski,et al.  Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry , 1999, Cell.

[32]  M. Götte,et al.  Functions of cell surface heparan sulfate proteoglycans. , 1999, Annual review of biochemistry.

[33]  Y. Bae,et al.  Star-Shaped Poly(ether−ester) Block Copolymers: Synthesis, Characterization, and Their Physical Properties , 1998 .

[34]  George M Whitesides,et al.  Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. , 1998, Angewandte Chemie.

[35]  R. Iozzo.  Matrix proteoglycans: from molecular design to cellular function. , 1998, Annual review of biochemistry.

[36]  R. Linhardt,et al.  Interaction of Secretory Leukocyte Protease Inhibitor with Heparin Inhibits Proteases Involved in Asthma* , 1998, The Journal of Biological Chemistry.

[37]  B. Keyt,et al.  Solution structure of the heparin-binding domain of vascular endothelial growth factor. , 1998, Structure.

[38]  D. Carson,et al.  A Peptide Sequence of Heparin/Heparan Sulfate (HP/HS)-interacting Protein Supports Selective, High Affinity Binding of HP/HS and Cell Attachment* , 1998, The Journal of Biological Chemistry.

[39]  Robert Langer,et al.  Pyranose Ring Flexibility. Mapping of Physical Data for Iduronate in Continuous Conformational Space , 1998 .

[40]  D. Hoke,et al.  Heparin/Heparan Sulfate (HP/HS) Interacting Protein (HIP) Supports Cell Attachment and Selective, High Affinity Binding of HP/HS* , 1997, The Journal of Biological Chemistry.

[41]  M. Nimni.  Polypeptide growth factors: targeted delivery systems. , 1997, Biomaterials.

[42]  Ziwei Huang,et al.  A natural motif approach to protein design: a synthetic leucine zipper peptide mimics the biological function of the platelet factor 4 protein , 1997, FEBS letters.

[43]  D. Carson,et al.  A heparin-binding synthetic peptide of heparin/heparan sulfate-interacting protein modulates blood coagulation activities. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Schuck,et al.  Use of surface plasmon resonance to probe the equilibrium and dynamic aspects of interactions between biological macromolecules. , 1997, Annual review of biophysics and biomolecular structure.

[45]  M Sobel,et al.  Structure-function relations of antithrombin III-heparin interactions as assessed by biophysical and biological assays and molecular modeling of peptide-pentasaccharide-docked complexes. , 1996, Archives of biochemistry and biophysics.

[46]  M. Salmivirta,et al.  Heparan sulfate : a piece of information , 2004 .

[47]  V. Hombach,et al.  Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. , 1996, Journal of molecular and cellular cardiology.

[48]  N. Karin,et al.  cDNA Cloning and Expression of HIP, a Novel Cell Surface Heparan Sulfate/Heparin-binding Protein of Human Uterine Epithelial Cells and Cell Lines (*) , 1996, The Journal of Biological Chemistry.

[49]  Hung V. Nguyen,et al.  The Carboxyl-terminal Domain(111165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency (*) , 1996, The Journal of Biological Chemistry.

[50]  B. Allolio,et al.  Antiproliferative and angiostatic activity of suramin analogues. , 1995, Cancer research.

[51]  Kinam Park,et al.  Polysaccharide hydrogels for protein drug delivery , 1995 .

[52]  M. Pantoliano,et al.  Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. , 1994, Biochemistry.

[53]  Robert B. Harris,et al.  Heparin binding domain peptides of antithrombin III: Analysis by isothermal titration calorimetry and circular dichroism spectroscopy , 1994, Protein science : a publication of the Protein Society.

[54]  D. Rifkin,et al.  Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. , 1994, The Journal of biological chemistry.

[55]  E. Grell,et al.  A new reagent for the cleavage of fully protected peptides synthesised on 2-chlorotrityl chloride resin , 1994 .

[56]  R. Danesi,et al.  Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane , 2007 .

[57]  M. Forster,et al.  N.m.r. and molecular-modelling studies of the solution conformation of heparin. , 1993, The Biochemical journal.

[58]  M. Sobel,et al.  Design and synthesis of a helix heparin-binding peptide. , 1992, Biochemistry.

[59]  E. Edelman,et al.  Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. , 1992, The Journal of clinical investigation.

[60]  J. Maraganore,et al.  Anticoagulant activity of synthetic hirudin peptides. , 1989, The Journal of biological chemistry.

[61]  P. B. Weisz,et al.  Control of angiogenesis with synthetic heparin substitutes. , 1989, Science.

[62]  P. Sinaÿ.  Active fragments of natural polysaccharides , 1989 .

[63]  G. Hortin,et al.  Identification of two sites of sulfation of human heparin cofactor II. , 1986, The Journal of biological chemistry.

[64]  D. Gospodarowicz,et al.  Heparin protects basic and acidic FGF from inactivation , 1986, Journal of cellular physiology.

[65]  J. Hofsteenge,et al.  Kinetics of the inhibition of thrombin by hirudin. , 1986, Biochemistry.

[66]  J. Holbrook,et al.  Low-resolution structure of the complex of human blood platelet factor 4 with heparin determined by small-angle neutron scattering. , 1986, Biochimica et biophysica acta.

[67]  M. Hosang.  Suramin binds to platelet‐derived growth factor and inhibits its biological activity , 1985, Journal of cellular biochemistry.

[68]  J. Møller,et al.  Use of flexible polymers as probes of glomerular pore size. , 1979, The American journal of physiology.

[69]  K. W. Bentley,et al.  Flavothebaone. Part VIII. Hofmann degradation of flavothebaone trimethyl ether ψ-methine methiodide , 1974 .

[70]  C. P. Carpenter,et al.  Renal excretion and volume distribution of some polyethylene glycols in the dog. , 1947, The American journal of physiology.